Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new...
By Denny Jacob Clinical stage immunotherapy company Alpine Immune Sciences shares rose 33%, to $13.96, after presenting findings on povetacicept in...
Alpine Immune Sciences, Inc. announced that the Company presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking poster session at the American Society...
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have been given a consensus recommendation of “Buy” by the seven research firms that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the […]
Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present...